Litcius/Paper detail

Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

Aditya H. Gaur, James McCarthy, John C. Panetta, Ronald H. Dallas, John Woodford, Li Tang, Amber M. Smith, Tracy B. Stewart, Kristen Branum, Burgess B. Freeman, Nehali Patel, Elizabeth John, Stephan Chalon, Shelley Ost, Ryan N. Heine, Julie Richardson, Robbin Christensen, Patricia M. Flynn, Yvonne Van Gessel, Branko Mitasev, Jörg J. Möhrle, Fabian Gusovsky, Lidiya Bebrevska, R. Kiplin Guy

2020The Lancet Infectious Diseases77 citationsDOI

Topics & Concepts

TolerabilityPharmacokineticsMedicineMalariaPlasmodium falciparumPharmacologyDosingCohortVolunteerInternal medicineAdverse effectImmunologyBiologyAgronomyMalaria Research and ControlPharmaceutical Quality and CounterfeitingDiverse Scientific Research Studies
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial | Litcius